New York State Common Retirement Fund trimmed its Regeneron stake by 5% in Q1, selling over 6,800 shares worth millions.

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

It is widely understood that employing debt to fund operations can act as a powerful financial tool. But debt doesn ...

Regeneron Pharmaceuticals Inc. research and ratings by Barron's. View RGO revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.

Several companies on the Wall Street have seen some Seeking Alpha analyst activity, including both upgrades and downgrades in rating. Chip designer Ambarella (AMBA) faces a downgrade following a 20% ...